179 results on '"Lasnon, Charline"'
Search Results
2. PET imaging and quantification of small animals using a clinical SiPM-based camera
3. Feasibility of Imaging Small Animals on a 360° Whole-Body Cadmium Zinc Telluride SPECT Camera: a Phantom Study
4. Fair play: towards gender equality in nuclear medicine
5. Artificial intelligence-based PET denoising could allow a two-fold reduction in [18F]FDG PET acquisition time in digital PET/CT
6. Advances in PET/CT Technology: An Update
7. The impact of introducing deep learning based [18F]FDG PET denoising on EORTC and PERCIST therapeutic response assessments in digital PET/CT.
8. F18-Choline PET/CT or MIBI SPECT/CT in the Surgical Management of Primary Hyperparathyroidism: A Diagnostic Randomized Clinical Trial.
9. Baseline and early 18F-FDG PET/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapy.
10. New PET technologies – embracing progress and pushing the limits
11. Revisiting detection of in-transit metastases in melanoma patients using digital 18F-FDG PET/CT with small-voxel reconstruction
12. Upfront F18-choline PET/CT versus Tc99m-sestaMIBI SPECT/CT guided surgery in primary hyperparathyroidism: the randomized phase III diagnostic trial APACH2
13. A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
14. More fat, less migration: breast density as a predictor of sentinel lymph node non-visualization in breast cancer
15. Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma
16. Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy
17. Can someone look after my children while I write this COVID-19 paper?
18. Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
19. HYPHYCA: a prospective study in 613 patients conducting a comprehensive analysis for predictive factors of physiological 18F-FDG anal uptake
20. Assessment of alteration in liver 18F–FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score
21. Reply to: “All that glitters is not gold – new reconstruction methods using Deauville criteria for patient reporting”
22. Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma
23. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs)
24. EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program
25. Comprehensive analysis of the influence of G-CSF on the biodistribution of 18F-FDG in lymphoma patients: insights for PET/CT scheduling
26. Implications of reconstruction protocol for histo-biological characterisation of breast cancers using FDG-PET radiomics
27. Combining baseline TMTV and gene profiling for a better risk stratification in diffuse large B cell lymphoma
28. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies
29. Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction
30. 18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer
31. Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
32. Reply to the Letter to the Editor from Peters et al: On the use of the liver as a reference organ for Deauville scoring in lymphoma patients and how it may be affected by liver steatosis
33. Deep Learning Denoising Improves and Homogenizes Patient [ 18 F]FDG PET Image Quality in Digital PET/CT.
34. Quantifying and correcting for tail vein extravasation in small animal PET scans in cancer research: is there an impact on therapy assessment?
35. NEMA NU 4-Optimized Reconstructions for Therapy Assessment in Cancer Research with the Inveon Small Animal PET/CT System
36. Patient’s weight: a neglected cause of variability in SUV measurements? A survey from an EARL accredited PET centre in 513 patients
37. Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic 18 F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma Patients.
38. Contrast-enhanced small-animal PET/CT in cancer research: strong improvement of diagnostic accuracy without significant alteration of quantitative accuracy and NEMA NU 4–2008 image quality parameters
39. Correction to: Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma
40. Artificial intelligence-based PET denoising could allow a two-fold reduction in [18F]FDG PET acquisition time in digital PET/CT.
41. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients
42. αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study
43. Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma.
44. End-of-treatment 18F-FDG PET/CT in diffuse large B cell lymphoma patients: ΔSUV outperforms Deauville score.
45. Women Authors in Nuclear Medicine Journals: a Survey from 2014 to 2020.
46. Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients.
47. Diuretic 18 F-FDG PET/CT for therapy monitoring in urothelial bladder cancer
48. Revisiting detection of in-transit metastases in melanoma patients using digital 18F-FDG PET/CT with small-voxel reconstruction.
49. Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers.
50. Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.